VBI Vaccines — Immuno-Oncology Summit 2017
25 slides from VBI Vaccines's conference presentation, Aug 30, 2017
Slide 1: Harnessing the Immunogenicity of Foreign Viral CMV Antigens to Target Solid Tumors
(VBI VACCINES Coma HARNESSING THE IMMUNOGENICITY OP FOREIGN VIRAL CMV ANTIGENSTO TARGET SOLID TUMORS NASDAQ: VBIV IMMUNO-ONCOLOGY SUMMIT TSX: VBV AUGUST 30 2017
Slide 2: Cautionary Statement Regarding Forward-Looking Information
Cautionary Statement Regarding Forward-Looking Information Certain statements in this presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation (collective
Slide 3: Agenda
li Agenda 2 3 Intro & eVLP Platform Overview Significance of CMV as a Tumor Target VBI-1901 IND-Enabling Data Summary
Slide 4: Convergence of Vaccinology & Immuno-oncology — Cancer Vaccines 3.0
Convergence of Vaccinology & Immuno-oncology — Cancer Vaccines 3.0 Live Viral Themes of Convergence: laccines ‘Reductionist’ Peptide Subunit vaccines * Antigen selection * Immunogenicity RecProtein +/- Adjuvants @ VLPs * Self vs Foreign Viral Vector mRNA & DNA 2 (?) « Antigen delivery (?) * Recognit
Slide 5: eVLP Platform: enveloped virus-like particles that leverage innate immune signaling
eVLP Platform: enveloped virus-like particles that leverage innate immune signaling to stimulate anti-tumor immunity eVLP Overview Customizable constructs that mimic enveloped viruses as they occur in nature: * Key structural components eVLP Features v Natively stimulate adaptive and innate immunity
Slide 6: VBI-1901: Rationally designed therapeutic CMV vaccine for solid tumors
VBI-1901: Rationally designed therapeutic CMV vaccine for solid tumors VBI-1901: Therapeutic CMV Schematic Virus-like Structure Stimulates Innate Immunity & Promotes Uptake by Antigen Presenting Cells (APCs) Antibody Targets gB ‘Foreign’ Tumor Associated Viral Antigens (TAVA) are naturally immunogen
Slide 7: Significance of CMV as a Tumor Target
Rl Vie! Significance of CMV as a Tumor “oy Target faa evbiz Soe NASDAQ: VBIV | TSX: VBV 7
Slide 8: Foreign viral antigens, like CMV, enable immune targeting in cold tumors
Foreign viral antigens, like CMV, enable immune targeting in “cold” tumors where checkpoints inhibitors have been less successful voi Occasional Neoantigen Formation Frequent Neoantigen Formation Typically “Colder” Tumors Typically “Hotter” Tumors Formation of neoantigens 1000 p= j| Frequently 8 Reg
Slide 9: Broad evidence supports CMV as a cancer immunotherapeutic target
Broad evidence supports CMV as a cancer immunotherapeutic target Body of Evidence Suggests a CMV Vaccine That Can Stimulate DCs & Restimulate CMV-Specific T-cells Has Potential for Clinical Efficacy * Prins RM (2008) ~ Autologous, GBM tumor lysate DC vaccine © Single imzn. increased CMV pp65-specifi
Slide 10: Duke-led study demonstrates CMV dendritic cell vaccines can increase pp65 immunity
Duke-led study demonstrates that CMV dendritic cell vaccines can increase pp65 immunity (Batich et al, 2017) Trial Design Clinical Results + 11 patients received at least 3 doses of pp65- * >3 times longer progression-free survival dentritic cells after dose-intensified temozolomide * >2 times longe
Slide 11: VBI-1901 IND-Enabling Data
VBI-1901 IND-Enabling Data ns, evbiz Xena NASDAQ; VBIV | TSX: VBV 11
Slide 12: VBI-1901: Elicits Balanced Cellular & Humoral Immunity
CD3*CD4*IFNy* (%) voi VBI-1901: Elicits Balanced Cellular & Humoral Immunity Tumor Clearance by CTLs is Known to be Enhanced by CD4 & Antibody Responses pp65-specific Th1 cells gB-specific CTLs gB-specific antibody response 2. - ' 3 = 6 3 3 & g 2 = = a 3 oO 2 = a < Oo Naive mice (n= 4 or 8/group) we
Slide 13: VBI-1901: Potential Off-the-Shelf Dendritic Cell Vaccine
VBI-1901: Potential “Off-the-Shelf” Dendritic Cell Vaccine VBI-1901 Recruits (CCL3) and Activates (IL-8) Dendritic Cells CCL3 IL-8 _ 8 = 250 = = D6 je ee = = er = CCL3: gB/pp65 eVLPs ce 100 = gBipp65 eVLPs 3 -® CCL3: Human serum albumin £199 == Human serum albumin 2 2 § 2 8 é 2 0 50 100 150 200 0 20
Slide 14: VBI-1901: Stimulates Innate Immunity
VBI-1901: Stimulates Innate Immunity eVLP particles stimulate IL-8 (independent of antigen) Inclusion of gB/pp65 antigens stimulates additional pro-inflammatory cytokines IL8 Monocytes Note: Human monocytes ‘0000 = were purified by negative som Mm Bipocs selection to >90% purity z eas and stimulated
Slide 15: VBI-1901: Stimulates Innate Immunity (CMV-gB driven)
OOOO eee VBI-1901: Stimulates Innate Immunity Antigen specific upregulation of pro-inflammatory cytokines is driven by CMV-gB voi 46% Gl gB/pp65 eVLPs HB gB/pp65 eVLPs + anti-gB mAb Cytokine Secretion (pg/ml) 3 >» so IN s NY, vy ; & s S i; ~ gB Monoclonal Can Neutralize Stimulation of Innate Cytokin
Slide 16: VBI-1901: Re-stimulates CMV-specific Immunity in Human Ex Vivo Samples
VBI-1901: Re-stimulates CMV-specific Immunity in Human Ex Vivo Samples Restimulation of CD4+ & CD8+ T-cells in Ex Stimulation of CCL3 in CMV+ Tumors — Vivo Human Samples Correlated to >O.S. by Mitchell et al (2015) = cD4*IFN-y* CD8*IFN-;* = 9 2 £ Oo pou 5 = 2 2 2 < ° g Z 1. ° s - ° 3 iof como 8 3 fe
Slide 17: VBI-1901: Boosts CMV pp65-specific IFN-y T cell Responses in Macaques
VBI-1901: Boosts CMV pp65-specific IFN-y T cell Responses in Macaques Batich et al (2017) Observed CD8 T-cell Immunity after 3-doses & Improved Overall Survival VBI-1901 Restimulates CD8 Immunity in CMV+ Monkeys — Basis for Clinical Evaluation VBI-1901 + GM-CSF (Two Doses) = 2 nN aoasg w <P Pre-vacc
Slide 18: VBI-1901: Overview of CMC Process
VBI-1901: Overview of CMC Process Process optimized to preserve particle integrity & meet FDA standards Cla (Depth filtration) j ow Assay Description Test Result Concentrate particles (Tangential flow filtra Residual host cell DNA 1.4 ng/ug pp65 (quantitative PCR) Inactivate residual host DNA and ad
Slide 19: VBI-1901: IND Enabling Tox & Safety
TTT VBI-1901: IND Enabling Tox & Safety * — Standard Toxicology v No adverse events seen with VBI-1901 v eVLPs already safely evaluated in Ph! * Biodistribution Study Y Vaccine observed at injection site for up to 14 days (depot effect) Y¥ No accumulation in major organs * — Off-target Toxicology Y
Slide 20: VBI's prophylactic CMV vaccine achieved dose-dependent immune responses
VBI’s prophylactic CMV vaccine (similar design to 1901) achieved dose-dependent immune responses against CMV (interim Ph1 data) After only two vaccinations @ 2.0ug, 100% of subjects seroconvert - Exceptionally immunogenic vaccine platform * Seroconversion* in 100% of subjects + eVLPs highly immunoge
Slide 21: Opportunity & Clinical Development Plan
Rl vbi Opportunity & Clinical “oy Development Plan a evbiz Soe NASDAQ: VBIV | TSX: VBV 2
Slide 22: Initial Clinical Development of VBI-1901 Will Focus on GBM
voi Initial Clinical Development of VBI-1901 Will Focus on GBM - A Profound Unmet Medical Need GBM is the most aggressive form of brain cancer No standard of care options after initial surgery/radiation/chemotherapy Invasive primary tumor margins and secondary tumors are interspersed among healthy g
Slide 23: VBI-1901 Comparison to Recent Clinical IO Advances in GBM
VBI-1901 Comparison to Recent Clinical 1O Advances in GBM Breadth of Reactivity may be an Important Parameter for Efficacy Company/Inst. Key Finding Take-Away Novartis - CTLO19 BMS - Checkmate 143 Merck ~ Keynote 028 Duke - Batich (et al) VBI Vaccines voi EGFRvIll specific CAR-T PD1, PDL1 pp65 loade
Slide 24: VBI-1901: Potential Off-the-Shelf Vaccine for CMV+ Solid Tumors
VBI-1901: Potential ‘Off-the-Shelf’ Vaccine for CMV+ Solid Tumors Leverages inherent immunogenicity of CMV to target CMV-positive Off-The-Shelf Design SUutelgs Easily manufactured and scalable CMV is expressed in over 90% of Glioblastoma (GBM), Breast, Colorectal & other solid tumors High unmet need
Slide 25: =VOI
wm, SS = o => =VOI G Zam VBI Vaccines, Inc. 222 Third Street, Suite 2241 Cambridge, MA 02142 (617) 830-3031 \’ Uf yii\ info@vbivaccines.com NASDAQ; VBIV | TSX: VBV